DE69022982D1 - Humanisierte antikörper. - Google Patents

Humanisierte antikörper.

Info

Publication number
DE69022982D1
DE69022982D1 DE69022982T DE69022982T DE69022982D1 DE 69022982 D1 DE69022982 D1 DE 69022982D1 DE 69022982 T DE69022982 T DE 69022982T DE 69022982 T DE69022982 T DE 69022982T DE 69022982 D1 DE69022982 D1 DE 69022982D1
Authority
DE
Germany
Prior art keywords
antibody
pref
derived
chain
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69022982T
Other languages
English (en)
Other versions
DE69022982T2 (de
Inventor
John Adair
Diljeet ATHWAL
John Emtage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10668300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69022982(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of DE69022982D1 publication Critical patent/DE69022982D1/de
Publication of DE69022982T2 publication Critical patent/DE69022982T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
DE69022982T 1989-12-21 1990-12-21 Humanisierte antikörper. Revoked DE69022982T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898928874A GB8928874D0 (en) 1989-12-21 1989-12-21 Humanised antibodies
PCT/GB1990/002017 WO1991009967A1 (en) 1989-12-21 1990-12-21 Humanised antibodies

Publications (2)

Publication Number Publication Date
DE69022982D1 true DE69022982D1 (de) 1995-11-16
DE69022982T2 DE69022982T2 (de) 1996-03-28

Family

ID=10668300

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69031591T Expired - Lifetime DE69031591T2 (de) 1989-12-21 1990-12-21 Cd4-spezifischer rekombinanter antikörper
DE69020544T Expired - Lifetime DE69020544T2 (de) 1989-12-21 1990-12-21 Cd3-spezifischer rekombinanter antikörper.
DE69033857T Revoked DE69033857T2 (de) 1989-12-21 1990-12-21 Humanisierte Antikörper
DE69022982T Revoked DE69022982T2 (de) 1989-12-21 1990-12-21 Humanisierte antikörper.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE69031591T Expired - Lifetime DE69031591T2 (de) 1989-12-21 1990-12-21 Cd4-spezifischer rekombinanter antikörper
DE69020544T Expired - Lifetime DE69020544T2 (de) 1989-12-21 1990-12-21 Cd3-spezifischer rekombinanter antikörper.
DE69033857T Revoked DE69033857T2 (de) 1989-12-21 1990-12-21 Humanisierte Antikörper

Country Status (21)

Country Link
US (10) US5929212A (de)
EP (5) EP0626390B1 (de)
JP (4) JPH04505398A (de)
KR (3) KR100191152B1 (de)
AT (4) ATE129017T1 (de)
AU (4) AU649645B2 (de)
BG (1) BG60462B1 (de)
BR (1) BR9007197A (de)
CA (3) CA2046904C (de)
DE (4) DE69031591T2 (de)
DK (4) DK0460171T3 (de)
ES (4) ES2165864T3 (de)
FI (4) FI108917B (de)
GB (4) GB8928874D0 (de)
GR (2) GR3017734T3 (de)
HU (4) HUT60786A (de)
NO (5) NO913229L (de)
RO (3) RO114298B1 (de)
RU (1) RU2112037C1 (de)
WO (3) WO1991009968A1 (de)
ZA (1) ZA9110129B (de)

Families Citing this family (1292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US6750325B1 (en) * 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6399062B1 (en) * 1990-11-06 2002-06-04 The United States Of America As Represented By The Secretary Of The Navy Murine monoclonal antibody protective against Plasmodium vivax malaria
WO1992009305A1 (en) * 1990-11-27 1992-06-11 Biogen, Inc. Anti cd-4 antibodies blocking hiv-induced syncytia
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9104498D0 (en) * 1991-03-04 1991-04-17 Ks Biomedix Ltd Antibody
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
AU668864B2 (en) * 1991-03-18 1996-05-23 Centocor Inc. Chimeric antibodies specific for human tumor necrosis factor
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
ATE188708T1 (de) * 1991-08-21 2000-01-15 Novartis Ag Antikörperderivate
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1993012220A1 (en) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
EP0625200B1 (de) * 1992-02-06 2005-05-11 Chiron Corporation Marker für krebs und biosynthetisches bindeprotein dafür
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) * 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
US6042828A (en) * 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO1995013094A1 (en) * 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US6214973B1 (en) * 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
EP0749488A1 (de) * 1994-03-03 1996-12-27 Genentech, Inc. Anti il - 8 monoklonale antikörper für die behandlung von entzündlichen erkrankungen
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
CA2186455A1 (en) * 1994-03-29 1995-10-05 Raymond John Owens Antibodies against e-selectin
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
JPH09509851A (ja) * 1994-12-23 1997-10-07 セルテック セラピューティックス リミテッド ヒトホスホジエステラーゼ型ｉｖｃ、並びにその生産および使用
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.
US6949244B1 (en) * 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
EP0840618B1 (de) * 1995-05-18 2003-04-23 Ortho-McNeil Pharmaceutical, Inc. Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti-cd4-antikoepern
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
ATE266726T1 (de) 1995-06-07 2004-05-15 Ortho Pharma Corp CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP0873363B1 (de) * 1995-06-14 2010-10-06 The Regents of The University of California Hochaffine humane antikörper gegen tumorantigene
DE19543039C1 (de) * 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
RO123028B1 (ro) * 1996-02-09 2010-07-30 Abbott Laboratories (Bermuda) Ltd. Anticorpi umani, care leagă tnf alpha uman
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
ATE248192T1 (de) 1996-06-07 2003-09-15 Neorx Corp HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU741338B2 (en) * 1996-09-20 2001-11-29 Bristol-Myers Squibb Company Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
JP4450870B2 (ja) 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
JP4330180B2 (ja) * 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
DE69836729T2 (de) * 1997-04-07 2007-12-13 Genentech, Inc., South San Francisco Anti-vefg antibodies
ES2361267T3 (es) * 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1724282B1 (de) 1997-05-21 2013-05-15 Merck Patent GmbH Verfahren zur Herstellung von nicht-immunogenen Proteinen
EP1020522B1 (de) * 1997-10-03 2007-09-19 Chugai Seiyaku Kabushiki Kaisha Natürlicher menschlicher antikörper
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
TR200003087T2 (tr) * 1998-04-21 2001-02-21 Micromet Ag Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
CA2327505A1 (en) * 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
EP1117808B1 (de) 1998-10-06 2004-12-29 Mark Aaron Emalfarb Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CN1333828B (zh) 1998-11-27 2015-05-13 Ucb医药有限公司 增加骨矿化的组合物和方法
EP1161451A4 (de) 1999-02-26 2006-05-17 Human Genome Sciences Inc Menschliches alpha-endokin und verfahren zu seiner verwendung
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
JP2003509078A (ja) * 1999-09-22 2003-03-11 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 細胞に基づくアッセイ
ATE388167T1 (de) * 1999-09-30 2008-03-15 Kyowa Hakko Kogyo Kk Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP2289550A3 (de) * 2000-01-27 2012-02-15 MedImmune, LLC Neutralisierende Antikörper mit ultrahoher Affinität
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
CA2399080C (en) * 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
EP1783227A1 (de) * 2000-02-03 2007-05-09 Millennium Pharmaceuticals, Inc. Humanisierte Antikörper gegen CCR2 und Verfahren zur deren Verwendung
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
KR100767146B1 (ko) 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
AU784677B2 (en) * 2000-03-02 2006-05-25 Abgenix, Inc. Human monoclonal antibodies against oxidized LDL receptor and pharmaceutical uses thereof
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
EP1832599A3 (de) 2000-04-12 2007-11-21 Human Genome Sciences, Inc. Albuminfusionsproteine
PT1283214E (pt) 2000-04-21 2007-03-30 Fuso Pharmaceutical Ind Novas colectinas
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
EP2431054A3 (de) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Menschlicher Tumornekrosefaktor Delta und Ypsilon
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
CA2425809A1 (en) 2000-10-13 2002-04-18 Biogen, Inc. Humanized anti-lt-.beta.-r antibodies
AU1994402A (en) 2000-11-28 2002-06-11 Mediummune Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
CA2433800C (en) 2001-01-05 2016-09-13 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
EP1366058B1 (de) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
DE60238987D1 (de) 2001-03-15 2011-03-03 Neogenix Oncology Inc Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
ATE470676T1 (de) 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
DK1572874T3 (da) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
DE60226036T9 (de) * 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
EP1944040B1 (de) 2001-08-17 2012-08-01 Washington University Assay-Verfahren für Alzheimer
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
WO2003025124A2 (en) * 2001-09-14 2003-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunoglobulin having particular framework scaffold and methods of making and using
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
JP4443923B2 (ja) * 2001-10-15 2010-03-31 イミューノメディクス、インコーポレイテッド 親和性向上剤
JP4347694B2 (ja) * 2001-10-16 2009-10-21 レイベン バイオテクノロジーズ，インコーポレイティド 癌関連抗原ｃｄ４６に結合する抗体およびその使用方法
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AU2002365926A1 (en) * 2001-10-25 2003-09-02 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
CA2469196A1 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Discovery of therapeutic products
US7754433B2 (en) * 2001-12-03 2010-07-13 Amgen Fremont Inc. Identification of high affinity molecules by limited dilution screening
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
EP2277910A1 (de) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin Fusionsproteine
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003104428A2 (en) 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003226065B2 (en) 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2003092597A2 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
HUE057124T2 (hu) 2002-05-02 2022-04-28 Wyeth Holdings Llc Calicheamicin származék - hordozó konjugátumok
AU2012244218C1 (en) * 2002-05-02 2016-12-15 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
JP4418745B2 (ja) 2002-05-28 2010-02-24 ユセベ ファルマ ソシエテ アノニム 抗体ｐｅｇ位置異性体、それを含む組成物及びその使用
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2487321A1 (en) 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AR040367A1 (es) 2002-07-01 2005-03-30 Biogen Inc Anticuerpos humanizados contra el receptor de linfotoxina beta
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
EP2371389A3 (de) 2002-08-14 2012-04-18 MacroGenics, Inc. FC-Gamma-RIIB-spezifische Antikörper und Verwendungsverfahren davon
AU2003268275C1 (en) 2002-08-29 2010-04-01 Cytocure Llc Methods for up-regulating antigen expression in tumors
US7803372B2 (en) 2002-10-08 2010-09-28 Immunomedics, Inc. Antibody therapy
JP4988201B2 (ja) 2002-10-16 2012-08-01 ユーロ−セルティーク エス．エイ． 細胞結合性ｃａ１２５／ｏ７７２ｐに結合する抗体およびその使用方法
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004110345A2 (en) * 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
AU2002368305A1 (en) * 2002-10-31 2004-05-25 Universita'degli Studi Di Roma "La Sapienza" Antimicrobial lipase antibodies their nucleotide and aminoacid sequences and uses thereof
EP3299393A1 (de) 2002-11-08 2018-03-28 Ablynx N.V. Gegen den tumornekrosefaktor-alpha gerichtete antikörper mit einfacher domäne und verwendungen dafür
AU2003295474B2 (en) * 2002-11-13 2009-07-30 Macrogenics West, Inc. Antigen PIPA and antibodies that bind thereto
ATE481422T1 (de) 2002-11-21 2010-10-15 Celltech R & D Inc Modulieren von immunantworten
EP1575516B1 (de) 2002-11-26 2012-05-30 Abbott Biotherapeutics Corp. Chimäre humanisierte antikörper gegen alpha5 beta1 integrin, die die angiogenese modulieren
US7276372B2 (en) 2002-12-20 2007-10-02 Pdl Biopharma, Inc. Antibodies against GPR64 and uses thereof
EP2368578A1 (de) 2003-01-09 2011-09-28 Macrogenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20060188512A1 (en) * 2003-02-01 2006-08-24 Ted Yednock Active immunization to generate antibodies to solble a-beta
ATE468886T1 (de) * 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1638587A4 (de) 2003-02-14 2007-04-18 Univ Missouri Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
SI1606409T1 (sl) 2003-03-19 2011-01-31 Biogen Idec Inc Vezavni protein receptorja Nogo
EP1460088A1 (de) * 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
CA2522957C (en) 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1629012B1 (de) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmazeutische zusammensetzungen, enthaltend bispezifische anti-cd3, anti-cd19-antikörperkonstrukte zur behandlung von mit b-zellen im zusammenhang stehenden erkrankungen
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
EP1641826A2 (de) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Verwendung der hydrophoben-interaktions-chromatographie oder hinge-regionen modifikationen zur herstellung homogener antikörperlösung
JP2008500005A (ja) 2003-07-15 2008-01-10 バロス リサーチ インスティテュート 癌及び感染症の免疫療法のための組成物及び方法
MEP31408A (en) * 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
WO2005009369A2 (en) * 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP1668111A4 (de) 2003-08-08 2008-07-02 Genenews Inc Osteoarthritis-biomarker und verwendungen davon
PT1656391E (pt) 2003-08-13 2010-12-06 Pfizer Prod Inc Anticorpos humanos modificados contra igf-ir
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
AU2004286198C1 (en) * 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
US20050042664A1 (en) * 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
BRPI0415457A (pt) * 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
EP2330201B1 (de) 2003-10-22 2017-04-05 Keck Graduate Institute Verfahren zur synthese heteromultimerer polypeptide in hefe unter verwendung einer haploidpaarungsstrategie
DE60334645D1 (de) 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
EP1695093A1 (de) * 2003-12-05 2006-08-30 multimmune GmbH Verbindungen und verfahren zur behandlung und diagnose von neoplastischen und infektiösen krankheiten
CA2550651C (en) 2003-12-23 2018-01-23 Tanox, Inc. Novel anti-il 13 antibodies and uses thereof
PT1704166E (pt) 2004-01-07 2015-09-04 Novartis Vaccines & Diagnostic Anticorpo monoclonal específico de m-csf e respetivos usos
WO2005068504A1 (ja) 2004-01-19 2005-07-28 Medical And Biological Laboratories Co., Ltd. 炎症性サイトカイン抑制剤
EP2340850A1 (de) 2004-02-10 2011-07-06 The Regents of the University of Colorado, a Body Corporate Hemmung von Faktor B, dem alternativen Komplement-Pfad und relevante Verfahren
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
EP1786463A4 (de) 2004-03-26 2009-05-20 Human Genome Sciences Inc Antikörper gegen nogo-rezeptor
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US9228008B2 (en) 2004-05-28 2016-01-05 Idexx Laboratories, Inc. Canine anti-CD20 antibodies
PT1781705E (pt) 2004-06-21 2014-12-23 Medarex Llc Anticorpos contra recetor i do interferão alfa e as suas utilizações
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
AU2005259992A1 (en) * 2004-06-25 2006-01-12 Medimmune, Llc Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
JP2008506681A (ja) 2004-07-16 2008-03-06 ファイザー・プロダクツ・インク 抗ｉｇｆ−１ｒ抗体を用いる非血液性の悪性腫瘍の併用療法
AU2005269265B2 (en) * 2004-08-02 2012-01-12 Zenyth Operations Pty Ltd A method of treating cancer comprising a VEGF-B antagonist
CN101014245A (zh) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 神经元功能中的taj
WO2006023544A2 (en) 2004-08-16 2006-03-02 Quark Biotech, Inc. Therapeutic uses of inhibitors of rtp801
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CA2585104A1 (en) 2004-12-06 2006-06-15 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
JP2008524247A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのアミロイドβ抗体
EP1838854B1 (de) * 2004-12-15 2012-10-31 Janssen Alzheimer Immunotherapy Antikörper, die Amyloid-Peptide erkennen
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
WO2006096565A2 (en) 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2006121852A2 (en) 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease
AU2006244180B2 (en) 2005-05-06 2012-03-01 Zymogenetics, Inc. IL-31 monoclonal antibodies and methods of use
WO2006121159A1 (ja) * 2005-05-12 2006-11-16 Kyowa Hakko Kogyo Co., Ltd. Cd10に特異的に反応するヒト型cdr移植抗体およびその抗体断片
EP2500037A3 (de) 2005-05-16 2012-10-24 Abbott Biotechnology Ltd Verwendung eines TNF-Hemmers zur Behandlung von erosiver Polyarthritis
PL1888640T3 (pl) 2005-05-18 2012-08-31 Ablynx Nv Ulepszone nanociała skierowane przeciwko czynnikowi martwicy nowotworów typu alfa
CA2606576A1 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
RS52861B (en) * 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF (ALPHA)
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
UA96922C2 (en) 2005-06-30 2011-12-26 Эббот Леборейториз Il-12/p40 binding protein
EP1904652A2 (de) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
CA2614640A1 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
PT2573114T (pt) 2005-08-10 2016-07-13 Macrogenics Inc Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
EP2500359A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
JP5106111B2 (ja) 2005-09-29 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｔ細胞接着分子およびそれに対する抗体
ES2542501T3 (es) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
US8239136B2 (en) 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
MX2008005764A (es) 2005-11-04 2008-11-18 Biogen Idec Inc Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
EP2543384A3 (de) 2005-12-02 2013-04-10 Biogen Idec MA Inc. Behandlung von Zuständen mithilfe von Demyelinisation
ZA200804594B (en) 2005-12-09 2010-08-25 Ucb Pharma Sa Antibody molecules having specificity for human IL-6
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
ES2595091T3 (es) 2005-12-21 2016-12-27 Amgen Research (Munich) Gmbh Composiciones farmacéuticas con resistencia a CEA soluble
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
JP2009523739A (ja) 2006-01-20 2009-06-25 ウィメンズ アンド チルドレンズ ヘルス リサーチ インスティテュート インコーポレーティッド 骨の病変の処置、予防、および診断の方法
EP2526968A3 (de) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo-Rezeptorantagonisten
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2498517T3 (es) 2006-03-10 2014-09-24 Wyeth Llc Anticuerpos anti-5T4 y usos de los mismos
DK2423229T3 (da) 2006-03-27 2013-08-05 Medimmune Ltd Bindingselement til GM-CSF-receptor
CN101454025B (zh) 2006-04-05 2014-01-01 艾伯维生物技术有限公司 抗体纯化
JP2009533347A (ja) 2006-04-07 2009-09-17 ネクター セラピューティックス エイエル，コーポレイション 抗ＴＮＦα抗体の複合体
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2007145941A2 (en) * 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
EP2032159B1 (de) 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
DK2029173T3 (en) 2006-06-26 2016-11-07 Macrogenics Inc FC-RIIB-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
NZ572765A (en) 2006-06-30 2012-08-31 Abbott Biotech Ltd Automatic injection device with rod driving syringe longitudinally split with radially compressible pair of wings along its length
KR101513498B1 (ko) 2006-06-30 2015-04-21 노보 노르디스크 에이/에스 항―ｎｋｇ2ａ 항체 및 이들의 용도
GB0613209D0 (en) 2006-07-03 2006-08-09 Ucb Sa Methods
WO2008010101A2 (en) 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody against epha2 for the treatment of cancer
EP2046826B1 (de) 2006-07-24 2011-09-14 Biorexis Pharmaceutical Corporation Exendin-fusionsproteine
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
EP2057193B1 (de) 2006-08-04 2013-12-18 Novartis AG Ephb3-spezifischer antikörper und verwendungen davon
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
SI2059535T1 (sl) 2006-08-18 2014-03-31 Novartis Ag Za prlr specifiäśno protitelo in njegove uporabe
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
BRPI0715660B8 (pt) 2006-09-01 2021-05-25 Zymogenetics Inc anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
ES2817756T3 (es) 2006-09-08 2021-04-08 Abbvie Bahamas Ltd Proteínas de unión a interleuquina-13
EP2407548A1 (de) 2006-10-16 2012-01-18 MedImmune, LLC Moleküle mit reduzierter Halbwertzeit, Zusammensetzungen und ihre Verwendung
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
CN103638521A (zh) 2006-11-17 2014-03-19 财团法人阪大微生物病研究会 神经延长促进剂及延长抑制剂
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
EP2101813B1 (de) 2006-11-27 2014-04-02 Patrys Limited Neues glykosyliertes zielpeptid in neoplastischen zellen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
EP2687232A1 (de) 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
WO2008073914A2 (en) 2006-12-10 2008-06-19 Dyadic International Inc. Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
ES2673153T3 (es) 2007-01-09 2018-06-20 Biogen Ma Inc. Anticuerpos Sp35 y usos de los mismos
ES2593789T3 (es) 2007-02-01 2016-12-13 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
EP1958645A1 (de) 2007-02-13 2008-08-20 Biomay AG Peptide abgeleitet vom Hauptallergens von Traubenkraut (Ambrosia artemisiifolia) und deren Anwendung
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
TWI417299B (zh) 2007-03-22 2013-12-01 Biogen Idec Inc 包括抗體、抗體衍生物及抗體片段之專一性地結合至ｃｄ１５４之結合蛋白及其用途
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2008136694A1 (en) 2007-05-04 2008-11-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
NO3072525T3 (de) 2007-05-14 2018-06-30
CA2687556A1 (en) 2007-05-17 2008-11-27 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
NZ581418A (en) * 2007-05-21 2012-08-31 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
EP2164514B1 (de) 2007-05-21 2016-12-14 AlderBio Holdings LLC Antikörper gegen il-6 und ihre verwendung
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
EP1997830A1 (de) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP3424951A1 (de) 2007-06-21 2019-01-09 MacroGenics, Inc. Kovalente diabodies und deren verwendung
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
MX338474B (es) 2007-08-29 2016-04-18 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
EP2570431A3 (de) 2007-08-30 2013-05-01 CureDM Group Holdings, LLC Zusammensetzungen und Verfahren zur Anwendung von Proinselzellpeptiden und Analoga Davon
US8840906B2 (en) * 2007-08-31 2014-09-23 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung disease and conditions
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
CA2736661A1 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
JP2010539243A (ja) 2007-09-18 2010-12-16 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
EP2535349A1 (de) 2007-09-26 2012-12-19 UCB Pharma S.A. Antikörperfusionen mit Doppelspezifität
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
ES2609918T3 (es) * 2007-10-05 2017-04-25 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2219452B1 (de) 2007-11-05 2015-10-14 MedImmune, LLC Verfahren zur behandlung von skleroderm
JP2011514881A (ja) 2007-11-09 2011-05-12 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ 免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用
EP2222700A2 (de) 2007-11-27 2010-09-01 Medtronic, Inc. Humanisierte anti-amyloid-beta-antikörper
EP2225275A4 (de) 2007-11-28 2013-04-03 Medimmune Llc Proteinformulierung
JP5744522B2 (ja) 2007-12-07 2015-07-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１に特異的なヒト化抗体分子
EP2222706B2 (de) 2007-12-14 2016-08-10 Novo Nordisk A/S Antikörper gegen menschliches nkg2d und gebrauch davon
AR069979A1 (es) 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
CA2710483C (en) 2007-12-26 2018-05-08 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
CN101952315B (zh) 2007-12-26 2015-04-01 生物测试股份公司 靶向cd138的试剂及其应用
EP2237792B1 (de) 2007-12-26 2017-05-24 Vaccinex, Inc. Anti-c35-antikörper-kombinationstherapien und verfahren
KR101654822B1 (ko) 2007-12-26 2016-09-06 바이오테스트 아게 Ｃｄ138 표적성 면역접합체 및 이의 용도
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
CA2711771C (en) * 2008-01-11 2017-01-24 Gene Techno Science Co., Ltd. Humanized anti-.alpha.9 integrin antibodies and the uses thereof
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
DK2238170T3 (en) 2008-01-31 2017-02-27 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
BR122020023189B1 (pt) 2008-02-08 2022-02-01 Astrazeneca Ab Uso de uma composição farmacêutica compreendendo um anticorpo específico para ifnar1
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2569217T3 (es) 2008-03-13 2016-05-09 Biotest Ag Agente para tratar enfermedades
AU2009224690B2 (en) 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
CN102027017A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
EP2260102A1 (de) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
JPWO2009119794A1 (ja) 2008-03-27 2011-07-28 タカラバイオ株式会社 感染症予防、治療剤
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
EP2281005B1 (de) 2008-04-03 2013-11-20 Vib Vzw Einzeldomänenantikörper, die dazu in der lage sind, die bace1-aktivität zu modulieren
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
AU2009238897B2 (en) 2008-04-24 2015-03-19 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
MY159667A (en) 2008-05-09 2017-01-13 Abbvie Inc Antibodies to receptor of advanced glycation end products (rage) and uses thereof
BRPI0911984A2 (pt) 2008-05-16 2016-09-20 Ablynx Nv sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
CA2726131C (en) 2008-05-29 2018-03-13 Baoming Jiang Expression and assembly of human group c rotavirus-like particles and uses thereof
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
CN102112495A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
NZ589795A (en) 2008-06-16 2013-02-22 Patrys Ltd Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
JP6100463B2 (ja) * 2008-06-25 2017-03-22 エスバテック − ア ノバルティス カンパニー エルエルシー ＴＮＦαを阻害する安定かつ可溶性の抗体
CN107090035A (zh) 2008-06-25 2017-08-25 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
SI2307454T1 (sl) 2008-06-25 2017-05-31 ESBA Tech, an Alcon Biomedical Research Unit LLC Stabilna in topna protitelesa, ki inhibirajo VEGF
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
EP2810654A1 (de) 2008-07-08 2014-12-10 AbbVie Inc. Prostaglandin-E2 bindende Proteine und ihre Verwendung
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
EP2324852B1 (de) 2008-08-07 2015-07-08 Nagasaki University Therapeutischer oder prophylaktischer wirkstoff für generalisiertes schmerzsyndrom
MX2011002478A (es) 2008-09-07 2011-04-05 Glyconex Inc Anticuerpo anti-glucoesfingolipido tipo i extendido, derivados del mismo y su uso.
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
WO2010037836A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
JP2012504946A (ja) 2008-10-07 2012-03-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血小板第４因子変異体１（ｐｆ４ｖ１）に対する中和抗体およびそのフラグメント
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010052288A1 (en) 2008-11-07 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
EP2191840A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Melphalan erkennen
EP2191841A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Vincristin erkennen
EP2191842A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Cytarabin erkennen
EP2191843A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Cyclophosphamid erkennen
EP2198884A1 (de) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Gegen die LG4-5-Domäne der alpha3-Kette von Humanlaminim-5 gerichtete monoklonale Antikörper
CN106432503B (zh) 2008-12-19 2020-03-06 宏观基因有限公司 共价双抗体及其用途
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
CA2749572A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010085510A1 (en) 2009-01-20 2010-07-29 Zadeh Homayoun H Antibody mediated osseous regeneration
US8383778B2 (en) 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2396035A4 (de) 2009-02-12 2012-09-12 Human Genome Sciences Inc Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
SG173620A1 (en) 2009-02-17 2011-09-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
RU2011140335A (ru) 2009-03-05 2013-04-10 Эбботт Лэборетриз Связывающие il-17 белки
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
US8735552B2 (en) 2009-03-10 2014-05-27 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized K33N monoclonal antibody
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
US8470320B2 (en) * 2009-03-16 2013-06-25 Cephalon Australia Pty. Ltd. Humanised antibodies with anti-tumour activity
EP3002296B1 (de) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla-antikörper und ihre verwendung
EP2411412B1 (de) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanisierte antikörper gegen licht und anwendungen davon
US20120070450A1 (en) 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
CN102388069B (zh) 2009-04-10 2016-01-20 埃博灵克斯股份有限公司 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
KR20110138412A (ko) 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝＦ-α 항체 및 그의 용도
CN104558179A (zh) 2009-04-27 2015-04-29 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗IL-3Rα抗体
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US8945567B2 (en) 2009-06-05 2015-02-03 Ablynx N.V. Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
EP2440934B1 (de) 2009-06-08 2014-07-16 Vib Vzw Screening von verbindungen zur modulation des gpr3-vermittelten beta-arrestin-signalweges und erzeugung des amyloid-beta-peptids
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP5944822B2 (ja) 2009-06-15 2016-07-05 フエー・イー・ベー・フエー・ゼツト・ウエー Ｂａｃｅ１抑制性抗体
WO2010148223A2 (en) 2009-06-17 2010-12-23 Facet Biotech Corporation Anti-vegf antibodies and their uses
RU2012101999A (ru) 2009-06-22 2013-07-27 МЕДИММЬЮН, ЭлЭлСи РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
EP2448593B1 (de) 2009-07-03 2020-11-25 Bionor Immuno AS Kombination oder fusion aus hiv-peptiden zur verwendung für hiv-imfpstoffzusammensetzungen oder als diagnostikum
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
AU2010286518C1 (en) 2009-08-29 2015-08-27 Abbvie Inc. Therapeutic DLL4 binding proteins
RU2012112524A (ru) 2009-08-31 2013-10-10 Эбботт Байотерапьютикс Корп. Использование популяции иммунорегуляторных nk клеток для мониторинга эффективности антител против il-2r у пациентов с рассеянным склерозом
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
EP2488658A4 (de) 2009-10-15 2013-06-19 Abbvie Inc Immunglobuline mit zweifacher variabler domäne und ihre verwendung
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
CN102791735B (zh) 2009-10-16 2016-05-18 瑟维尔实验室 抗前胃泌素的单克隆抗体及其用途
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2639056T3 (es) 2009-10-28 2017-10-25 Abbvie Biotherapeutics Inc. Anticuerpos anti-EGFR y sus usos
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US20110104153A1 (en) 2009-10-30 2011-05-05 Facet Biotech Corporation Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
CN102740885B (zh) 2009-11-05 2015-04-01 梯瓦制药澳大利亚私人有限公司 涉及突变的kras或braf基因的癌症的治疗
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US8790887B2 (en) 2009-12-04 2014-07-29 Vib Vzw Screening methods for compounds that modulate ARF-6 mediated endosomal redistribution
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
EP2513148B1 (de) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2-antikörper und ihre verwendung
CA2785587A1 (en) 2009-12-23 2011-06-30 4-Antibody Ag Binding members for human cytomegalovirus
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9487582B2 (en) 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011116954A2 (en) 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CA2796215C (en) 2010-04-14 2021-05-18 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
ME03813B (de) 2010-04-16 2021-04-20 Biogen Ma Inc Anti-vla-4 antikörper
US20130034543A1 (en) 2010-04-19 2013-02-07 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Modulating xrn1
DK2571532T3 (en) 2010-05-14 2017-08-28 Abbvie Inc IL-1 BINDING PROTEINS
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
EP2580239A1 (de) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
JP6029581B2 (ja) 2010-06-19 2016-11-24 メモリアル スローン−ケタリング キャンサー センター 抗ｇｄ２抗体
ES2706913T3 (es) 2010-06-25 2019-04-01 Univ Aston Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
EP2596025B1 (de) 2010-07-23 2018-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Gegen co-029 gerichtete krebstherapieverfahren
US10533050B2 (en) 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
EP2598882B1 (de) 2010-07-30 2017-07-26 AC Immune S.A. Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
EP3252072A3 (de) 2010-08-03 2018-03-14 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne und verwendungen davon
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
PL3333188T3 (pl) 2010-08-19 2022-05-09 Zoetis Belgium S.A. Przeciwciała anty-ngf i ich zastosowanie
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
CA2813133C (en) 2010-10-01 2023-10-31 National Research Council Of Canada Anti-ceacam6 antibodies and uses thereof
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
US9771416B2 (en) 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
JP6006640B2 (ja) 2010-10-29 2016-10-12 株式会社ペルセウスプロテオミクス 高い内在化能力を有する抗ｃｄｈ３抗体
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
EA029419B1 (ru) 2010-11-19 2018-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Нейтрализующие антитела против ccl20
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
KR20140003467A (ko) 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
EP2655417A2 (de) 2010-12-21 2013-10-30 AbbVie Inc. Il-1 alpha- und -beta-bispezifische immunglobuline mit zweifacher variabler domäne und ihre verwendung
CA2824279A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
KR101950306B1 (ko) 2011-01-14 2019-02-20 유씨비 바이오파마 에스피알엘 Ｉｌ-17ａ 및 ｉｌ-17ｆ에 결합하는 항체 분자
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
EP3763740A1 (de) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit-antikörper und verwendungen davon
WO2012110500A1 (en) 2011-02-15 2012-08-23 Vib Vzw Means and methods for improvement of synaptic dysfunction disorders
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
WO2012118042A1 (ja) 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20140056897A1 (en) 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
EA035351B1 (ru) 2011-03-31 2020-06-01 Инсэрм (Инститют Насиональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Антитела, направленные против icos, и их применения
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
BR112013027224A8 (pt) 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
PE20141672A1 (es) 2011-05-02 2014-11-26 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-alfa4�7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR102101806B1 (ko) 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
CN108329391A (zh) 2011-05-27 2018-07-27 埃博灵克斯股份有限公司 使用rankl结合肽抑制骨质吸收
US9181553B2 (en) 2011-06-06 2015-11-10 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Method of treatment of breast cancers over-expressing the SHP2 signature genes
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
EP3150632B1 (de) 2011-06-10 2020-04-08 Her Majesty The Queen in right of Canada, as represented by the Minister of National Defence Anti-ricin-antikörper und verwendungen davon
BR112013032899A2 (pt) 2011-06-22 2017-01-24 Inserm Inst Nat De La Santé Et De La Rech Médicale anticorpos anti-axl e utilizações dos mesmos
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
EP2543677A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543678A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543679A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
KR20140061403A (ko) 2011-07-13 2014-05-21 애브비 인코포레이티드 항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
EP2756094B1 (de) 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antikörper und ihre verwendungen
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
WO2013036872A1 (en) 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
JP6152107B2 (ja) 2011-09-16 2017-06-21 ユセベ ファルマ ソシエテ アノニム クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
CN103827145A (zh) 2011-09-21 2014-05-28 富士瑞必欧株式会社 相对于亲和性复合物的抗体
SG11201400881SA (en) 2011-09-23 2014-04-28 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
WO2013053767A1 (en) 2011-10-10 2013-04-18 Medimmune Limited Treatment for rheumatoid arthritis
RU2014120981A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммунные связывающие агенты против склеростина
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
EP2773373B1 (de) 2011-11-01 2018-08-22 Bionomics, Inc. Verfahren zur blockierung eines krebsstammzellenwachstums
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
EP2776838A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Frühe diagnose neurodegenerativer erkrankungen
EP2776022A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
EP2776565A1 (de) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des nervensystems
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
BR112014011304B1 (pt) 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2599496A1 (de) 2011-11-30 2013-06-05 Kenta Biotech AG Neuartige Targets von Acinetobacter baumannii
US9416179B2 (en) 2011-12-05 2016-08-16 X-Body, Inc. PDGF receptor beta binding polypeptides
MX358680B (es) 2011-12-08 2018-08-31 Biotest Ag Usos de inmunoconjugados dirigidos a cd138.
EP3539982A3 (de) 2011-12-23 2020-01-15 Pfizer Inc Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
EP2794660A2 (de) 2011-12-23 2014-10-29 Phenoquest AG Antikörper zur behandlung und diagnose von affektiven störungen und angstzuständen
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
SG10201700735PA (en) 2012-01-20 2017-02-27 Genzyme Corp Anti-cxcr3 antibodies
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
CA2864092C (en) 2012-02-10 2021-06-29 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
EP2814842B1 (de) 2012-02-15 2018-08-22 Novo Nordisk A/S Antikörper die das peptidoglycan-erkennungs-protein erkennen
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP2814844B1 (de) 2012-02-15 2017-08-02 Novo Nordisk A/S Antikörper, die den auslösenden rezeptor binden und blockieren, der auf myeloid-zellen-1 (trem-1) exprimiert ist
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
PL2831113T3 (pl) 2012-03-28 2018-08-31 Sanofi Przeciwciała przeciwko ligandom receptora bradykininy B1
EP2831112A1 (de) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
ES2719495T3 (es) * 2012-05-07 2019-07-10 Dartmouth College Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
WO2013172951A1 (en) 2012-05-15 2013-11-21 Morphotek, Inc. Methods for treatment of gastric cancer
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
CN104717974A (zh) 2012-06-06 2015-06-17 比奥诺尔免疫有限公司 疫苗
EP2864355B1 (de) 2012-06-25 2016-10-12 Orega Biotech Il-17-antagonistenantikörper
US10048253B2 (en) 2012-06-28 2018-08-14 Ucb Biopharma Sprl Method for identifying compounds of therapeutic interest
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
WO2014011955A2 (en) 2012-07-12 2014-01-16 Abbvie, Inc. Il-1 binding proteins
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP2872526B1 (de) 2012-07-13 2020-04-01 The Trustees of the University of Pennsylvania Verstärkung der aktivität von car-t-zellen durch miteinführung eines bispezifischen antikörpers
CN110256559B (zh) 2012-07-25 2023-05-26 塞尔德克斯医疗公司 抗kit抗体及其用途
EP2890782A1 (de) 2012-09-02 2015-07-08 AbbVie Inc. Verfahren zur steuerung einer proteinheterogenität
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
NO2760138T3 (de) 2012-10-01 2018-08-04
EP2904106A4 (de) 2012-10-01 2016-05-11 Univ Pennsylvania Zusammensetzungen und verfahren zum anzielung von stromazellen zur behandlung von krebs
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014060444A1 (en) 2012-10-15 2014-04-24 Medimmune Limited Antibodies to amyloid beta
AU2013334451A1 (en) 2012-10-24 2015-06-04 National Research Council Of Canada Anti-Campylobacter jejuni antibodies and uses therefor
TW202014439A (zh) 2012-11-01 2020-04-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
EP2916872B1 (de) 2012-11-09 2019-02-27 Innate Pharma Kennungen für tgase-vermittelte konjugation
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP2733153A1 (de) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
CN104870423A (zh) 2012-11-16 2015-08-26 加利福尼亚大学董事会 用于蛋白质化学修饰的pictet-spengler连接反应
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
RS55987B1 (sr) 2012-11-20 2017-09-29 Sanofi Sa Anti-ceacam5 antitela i njihova primena
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
WO2014083379A1 (en) 2012-11-30 2014-06-05 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
WO2014100439A2 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
AU2013369339B2 (en) 2012-12-27 2018-11-15 Sanofi Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof
RU2015126663A (ru) 2013-01-28 2017-03-10 Эвек Инк. Гуманизированное антитело против hmgb1 или антиген-связывающий фрагмент указанного антитела
EP2951199A4 (de) 2013-01-31 2016-07-20 Univ Jefferson Fusionsproteine zur modulation von regulatorischen und effektor-t-zellen
CA2901960C (en) 2013-02-20 2022-10-04 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
ES2814962T3 (es) 2013-02-20 2021-03-29 Novartis Ag Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
IL292978A (en) 2013-03-13 2022-07-01 Univ California Preparations containing antibodies against cd-38 carfilzomib
WO2014143343A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
MX362075B (es) 2013-03-14 2019-01-07 Abbott Lab Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
MX368665B (es) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
CN105121470A (zh) 2013-03-15 2015-12-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
EP2981822B1 (de) 2013-05-06 2020-09-02 Scholar Rock, Inc. Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
KR20160129698A (ko) 2013-05-24 2016-11-09 메디뮨 엘엘씨 항-b7-h5 항체 및 이의 용도
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (de) 2013-06-21 2016-04-27 Innate Pharma Enzymatische konjugation von polypeptiden
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
PT3406633T (pt) 2013-07-25 2022-05-04 Cytomx Therapeutics Inc Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
EP3030902B1 (de) 2013-08-07 2019-09-25 Friedrich Miescher Institute for Biomedical Research Neues screening-verfahren zur behandlung von friedreich-ataxie
CN105705520B (zh) 2013-08-13 2020-09-25 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
US20160193308A1 (en) 2013-09-04 2016-07-07 Osaka University Dpp-4-targeting vaccine for treating diabetes
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US9481729B2 (en) 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
CA2924252C (en) 2013-09-16 2022-01-04 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
EP3052640A2 (de) 2013-10-04 2016-08-10 AbbVie Inc. Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
CA2927968C (en) 2013-10-25 2023-02-21 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
WO2015066027A2 (en) 2013-10-28 2015-05-07 Dots Devices, Inc. Allergen detection
AU2014342103B2 (en) 2013-10-31 2020-06-04 Sanofi-Aventis U.S. Llc. Specific anti-CD38 antibodies for treating human cancers
KR20160101909A (ko) 2013-11-07 2016-08-26 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 뉴레귤린 알로스테릭 항-her3 항체
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
WO2015088346A1 (en) 2013-12-13 2015-06-18 Rijksuniversiteit Groningen Antibodies against staphylococcus aureus and uses thereof.
CA2933199A1 (en) 2013-12-16 2015-06-25 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
EP3087101A4 (de) 2013-12-20 2017-12-06 Novartis AG Regulierbarer chimärer antigenrezeptor
LT3083680T (lt) 2013-12-20 2020-04-10 F. Hoffmann-La Roche Ag Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
WO2015099167A1 (ja) 2013-12-27 2015-07-02 国立大学法人大阪大学 Ｉｌ－１７ａを標的とするワクチン
EP2893939A1 (de) 2014-01-10 2015-07-15 Netris Pharma Anti-Netrin-1-Antikörper
EP4303229A3 (de) 2014-01-21 2024-04-17 Novartis AG Verbessertes antigen mit car-t-zellfähigkeit durch co-einführung von co-stimulatorischen molekülen
WO2015130416A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
CA2942152C (en) 2014-03-06 2023-08-01 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
JP6541236B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
CN113150163A (zh) 2014-03-21 2021-07-23 X博迪公司 双特异性抗原结合多肽
CN106536556B (zh) 2014-04-04 2020-02-07 生态学有限公司 结合lgr5的人源化抗体
CA2940671A1 (en) 2014-04-07 2015-10-15 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
ES2924393T3 (es) 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
WO2015164364A2 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
RS61516B1 (sr) 2014-04-30 2021-03-31 Pfizer Konjugati anti-ptk7 antitelo-lek
US20170267780A1 (en) 2014-05-16 2017-09-21 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
JP6668260B2 (ja) 2014-06-06 2020-03-18 レッドウッド バイオサイエンス， インコーポレイテッド 抗ｈｅｒ２抗体−メイタンシンコンジュゲート及びその方法
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2015198202A1 (en) 2014-06-23 2015-12-30 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
MX2017000484A (es) 2014-07-17 2017-05-01 Novo Nordisk As Mutagenesis dirigida al sitio anticuerpos receptor desencadenante expresado en las celulas mieloides de tipo 1 (trem-1) para reducir la viscosidad.
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
RU2747384C2 (ru) 2014-07-21 2021-05-04 Новартис Аг Лечение рака с помощью химерного антигенного рецептора к cd33
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
AU2015295349B2 (en) 2014-07-29 2020-09-24 Cellectis ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
KR20240011258A (ko) 2014-09-02 2024-01-25 이뮤노젠 아이엔씨 항체 약물 컨쥬게이트 조성물의 제형화 방법
US10759868B2 (en) 2014-09-04 2020-09-01 Cellectis Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy
EP3722315A1 (de) 2014-09-05 2020-10-14 Janssen Pharmaceutica NV Cd123-bindende wirkstoffe und verwendungen davon
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
EP3967709A1 (de) 2014-09-17 2022-03-16 Novartis AG Targeting von zytotoxischen zellen mit chimären rezeptoren zur adoptiven immuntherapie
US10080790B2 (en) 2014-09-19 2018-09-25 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
WO2016054354A1 (en) * 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
CA3001724A1 (en) 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
WO2016065329A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
AU2015339106B2 (en) 2014-10-31 2020-07-02 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding T cells
EA201790953A1 (ru) 2014-10-31 2017-10-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Изменение экспрессии гена в cart-клетках и их применения
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA2967222C (en) 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3227341A1 (de) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutante calreticulin-antikörper und deren verwendung bei der diagnose und therapie von myeloiden malignomen
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
DK3029137T3 (en) 2014-12-06 2019-04-08 Gemoab Monoclonals Gmbh GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF
KR20170093943A (ko) 2014-12-09 2017-08-16 애브비 인코포레이티드 낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체
US20170182179A1 (en) 2014-12-09 2017-06-29 Abbvie Inc. Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
PT3333191T (pt) 2014-12-11 2020-12-15 Pf Medicament Anticorpos anti-c10orf54 e suas utilizações
MX2017007381A (es) 2014-12-11 2017-11-06 Inbiomotion Sl Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
JP6827928B2 (ja) 2014-12-19 2021-02-10 ユニヴェルシテ・ドゥ・ナント 抗ｉｌ−３４抗体
MX2017007826A (es) * 2014-12-19 2018-02-13 Biotecnol Ltd Proteina de fusion que conprende tres dominios de union a 5t4 y cd3.
US10221248B2 (en) 2014-12-22 2019-03-05 The Rockefeller University Anti-MERTK agonistic antibodies and uses thereof
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
JP7152156B2 (ja) 2015-01-14 2022-10-12 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 抗ｌａｐモノクローナル抗体による癌の処置
BR112017014805A2 (pt) 2015-01-23 2018-01-09 Sanofi anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123
JP2018504144A (ja) 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｌｌ１特異的多鎖キメラ抗原受容体
EP4223873A3 (de) 2015-01-31 2023-09-06 The Trustees of the University of Pennsylvania Zusammensetzungen und verfahren zur t-zell-freisetzung von therapeutischen molekülen
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
SG10201907901XA (en) 2015-03-03 2019-10-30 Kymab Ltd Antibodies, uses & methods
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
WO2016149096A1 (en) 2015-03-13 2016-09-22 President And Fellows Of Harvard College Determination of cells using amplification
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
EP3270937A4 (de) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Fragmente zur bindung des anti-mica-antigens, fusionsmoleküle, expressionszellen und verfahren zur verwendung
US20180071413A1 (en) 2015-04-07 2018-03-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non-invasive imaging of tumor pd-l1 expression
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2983898A1 (en) 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
CN107667116A (zh) 2015-04-30 2018-02-06 哈佛学院院长及董事 治疗代谢病症的抗‑ap2 抗体及抗原结合剂
JP2018515603A (ja) 2015-05-04 2018-06-14 ビオノル・イムノ・アクシェセルスカプＢｉｏｎｏｒ Ｉｍｍｕｎｏ ＡＳ Ｈｉｖワクチン用の投薬レジメン
BR112017023829A2 (pt) 2015-05-06 2018-07-31 Janssen Biotech Inc agentes de ligação biespecíficos de antígeno de membrana específico da próstata (psma) e usos dos mesmos
EA201792451A1 (ru) 2015-05-07 2018-05-31 Агенус Инк. Антитела к ox40 и способы их применения
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
EP3294773A1 (de) 2015-05-15 2018-03-21 The General Hospital Corporation Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
EP3466967A1 (de) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
EP3298046A1 (de) 2015-05-20 2018-03-28 Cellectis Anti-gd3-spezifische chimäre antigenrezeptoren für krebsimmuntherapie
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016189045A1 (en) 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
RS60792B1 (sr) 2015-05-29 2020-10-30 Agenus Inc Anti-ctla-4 antitela i postupci za njihovu primenu
CR20170592A (es) 2015-05-29 2018-02-13 Abbvie Inc Anticuerpos anti-cd40 y sus usos
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
ES2809728T3 (es) 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
MA41670A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
BR112017028101A2 (pt) 2015-07-06 2018-09-04 Ucb Biopharma Sprl anticorpos de ligação à tau
US20180201687A1 (en) 2015-07-07 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to myosin 18a and uses thereof
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
WO2017025458A1 (en) 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
JP2018522907A (ja) 2015-08-11 2018-08-16 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞
EP4218777A3 (de) 2015-08-28 2023-08-23 The Trustees of the University of Pennsylvania Verfahren und zusammensetzungen für zellen, die ein chimäres intrazelluläres signalmolekül exprimieren
CN108135932A (zh) 2015-08-28 2018-06-08 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
KR20180067676A (ko) 2015-10-27 2018-06-20 유씨비 바이오파마 에스피알엘 항-il-17a/f 항체를 사용한 치료 방법
EP3368567A4 (de) 2015-10-28 2019-05-22 Yale University Humanisierter anti-dkk2-antikörper und verwendungen davon
WO2017072669A1 (en) 2015-10-28 2017-05-04 Friedrich Miescher Institute For Biomedical Research Tenascin-w and biliary tract cancers
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
CN108350078A (zh) 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
WO2017079419A1 (en) 2015-11-05 2017-05-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
IL258768B2 (en) 2015-11-12 2023-11-01 Siamab Therapeutics Inc Compounds interacting with glycans and methods of use
FI3380525T3 (fi) 2015-11-25 2024-01-30 Immunogen Inc Lääkeformulaatioita ja niiden käyttömenetelmiä
JP2019501124A (ja) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
JP2019500327A (ja) 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
ES2861449T3 (es) 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
WO2017096361A1 (en) 2015-12-04 2017-06-08 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
IL296354B1 (en) 2015-12-15 2024-03-01 Oncoc4 Inc Chimeric and humanized monoclonal antibodies against CTLA-4 and their uses
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
CN108700586A (zh) 2015-12-31 2018-10-23 Syncerus有限责任公司 用于评估癌症发生的风险的组合物和方法
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
US20230183346A1 (en) 2016-02-26 2023-06-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
NZ745263A (en) 2016-03-02 2022-07-01 Idexx Lab Inc Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN109195630A (zh) 2016-03-15 2019-01-11 阿斯利康(瑞典)有限公司 用于治疗与淀粉样蛋白β累积相关的病症的BACE抑制剂和抗体或抗原结合片段的组合
IL261261B2 (en) 2016-03-17 2024-04-01 Numab Therapeutics AG Antibodies against TNF-ALPHA and their functional fragments
CN109153718B (zh) 2016-03-17 2022-02-08 努玛治疗有限公司 抗TNFα抗体及其功能片段
LT3219727T (lt) 2016-03-17 2021-02-10 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
PL3219726T3 (pl) 2016-03-17 2021-07-19 Tillotts Pharma Ag Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
WO2017158084A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
CN109715207B (zh) 2016-03-29 2023-03-31 南加利福尼亚大学 靶向癌症的嵌合抗原受体
KR20220133318A (ko) 2016-04-15 2022-10-04 노파르티스 아게 선택적 단백질 발현을 위한 조성물 및 방법
CN114617962A (zh) 2016-04-27 2022-06-14 艾伯维公司 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
BR112018071288A2 (pt) 2016-05-01 2019-02-26 Ucb Biopharma Sprl dominio de ligação de carreador de proteína sérica de afinidade modificada
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
ES2864150T3 (es) 2016-05-17 2021-10-13 Abbvie Biotherapeutics Inc Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
CN109415441B (zh) 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
KR20220028143A (ko) 2016-05-27 2022-03-08 애브비 바이오테라퓨틱스 인크. 항-cd40 항체 및 이의 용도
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
EP3464375A2 (de) 2016-06-02 2019-04-10 Novartis AG Therapeutische schemata für chimäre antigenrezeptor(car)-exprimierende zellen
RU2764651C2 (ru) 2016-06-08 2022-01-19 Эббви Инк. Антитела к в7-н3 и конъюгаты антитела и лекарственного средства
AU2017279554A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
MX2018015277A (es) 2016-06-08 2019-09-06 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR20190079713A (ko) 2016-06-13 2019-07-05 아이-맵 항-pd-l1 항체 및 이것의 사용
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
JP7432363B2 (ja) 2016-06-21 2024-02-16 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CA3030841A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
WO2018013918A2 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CA3031289A1 (en) 2016-07-18 2018-01-25 Helix Biopharma Corp. Car immune cells to treat cancer
EP3491016A1 (de) 2016-07-28 2019-06-05 Novartis AG Kombinationstherapien von chimären antigenrezeptoren und pd-1-inhibitoren
JP7219207B2 (ja) 2016-07-29 2023-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 腫瘍関連マクロファージを標的化する抗体及びその使用
AU2017306267A1 (en) 2016-08-01 2019-02-14 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-M2 macrophage molecule
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
SG11201901597UA (en) 2016-08-26 2019-03-28 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
WO2018041838A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
IL306104A (en) 2016-09-14 2023-11-01 Abbvie Biotherapeutics Inc Antibodies against (CD27) PD-1
UA126384C2 (uk) 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
PT3328887T (pt) 2016-09-19 2021-10-19 I Mab Biopharma Hangzhou Co Ltd Anticorpos anti-gm-csf e suas utilizações
EP3515478B1 (de) 2016-09-21 2024-02-28 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
KR20190058509A (ko) 2016-10-07 2019-05-29 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 t-세포 수용체 리프로그래밍을 위한 조성물 및 방법
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
EP3526256A1 (de) 2016-10-11 2019-08-21 Agenus Inc. Anti-lag-3-antikörper und verfahren zur verwendung davon
EP3526248A4 (de) 2016-10-17 2020-07-08 Musc Foundation for Research Development Zusammensetzungen und verfahren zur behandlung von läsionen des zentralnervensystems
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
KR102539159B1 (ko) 2016-11-07 2023-06-02 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
CN108367075B (zh) 2016-11-23 2022-08-09 免疫方舟医药技术股份有限公司 4-1bb结合蛋白及其用途
KR20230037664A (ko) 2016-12-07 2023-03-16 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
ES2813057T3 (es) 2016-12-15 2021-03-22 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
US11434299B2 (en) 2016-12-21 2022-09-06 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
WO2018119299A1 (en) 2016-12-22 2018-06-28 Sanofi Humanized cxcr3 antibodies with depleting activity and methods of use thereof
TW201840585A (zh) 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
US20190315852A1 (en) 2017-01-05 2019-10-17 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
WO2018127791A2 (en) 2017-01-06 2018-07-12 Biosion, Inc. Erbb2 antibodies and uses therefore
MX2019007848A (es) 2017-01-20 2019-09-09 Tayu Huaxia Biotech Medical Group Co Ltd Anticuerpos anti-pd-1 y usos de los mismos.
MY188386A (en) 2017-01-24 2021-12-07 I Mab Biopharma Us Ltd Anti-cd73 antibodies and uses thereof
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
EP3354278A1 (de) 2017-01-31 2018-08-01 Sanofi Nervenzellschutzwirkung von spezifischen antikörpern für die protofibrillenform des beta-amyloid-peptids
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
MA47442A (fr) 2017-02-07 2019-12-18 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP3589662A4 (de) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Induzierbares monovalentes antigenbindendes protein
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3596124A1 (de) 2017-03-16 2020-01-22 Innate Pharma Zusammensetzungen und verfahren zur behandlung von krebs
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
CN110612309A (zh) 2017-03-27 2019-12-24 细胞基因公司 用于降低免疫原性的方法和组合物
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
CA3059366A1 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
KR20200014276A (ko) 2017-04-14 2020-02-10 가마맵스 파마 암을 예방 또는 치료하기 위한 amhrii-결합 화합물
US20230227566A1 (en) 2017-04-14 2023-07-20 Gamamabs Pharma Amhrii-binding compounds for preventing or treating lung cancers
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
ES2952961T3 (es) 2017-05-01 2023-11-07 Agenus Inc Anticuerpos anti-TIGIT y métodos de uso de los mismos
KR20220147684A (ko) * 2017-05-10 2022-11-03 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 최적화된 핵산 항체 작제물
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
AU2018265860B2 (en) 2017-05-12 2022-08-11 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN110662760A (zh) 2017-05-12 2020-01-07 奥古斯塔大学研究所公司 人甲胎蛋白特异性t细胞受体及其用途
CN111278459A (zh) 2017-05-19 2020-06-12 赛达克斯制药股份有限公司 组合疗法
AU2018277545A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
EP3409688A1 (de) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topische behandlung von entzündlicher darmerkrankung unter verwendung von anti-tnf-alpha antikörpern und fragmenten davon
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CA3063652A1 (en) 2017-06-01 2018-12-06 Psioxus Therapeutics Limited Oncolytic virus and method
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
EP3635007A1 (de) 2017-06-06 2020-04-15 STCube & Co., Inc. Verfahren zur behandlung von krebs unter verwendung von antikörpern und molekülen, die an btn1a1 oder btn1a1-liganden binden
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
KR102324568B1 (ko) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 HIV gp120 및 CD3을 표적화하는 다중특이적 항체
WO2019005756A1 (en) 2017-06-28 2019-01-03 The Rockefeller University CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
CN111491661A (zh) 2017-07-27 2020-08-04 诺莫坎制药有限责任公司 M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途
CN117050176A (zh) * 2017-07-31 2023-11-14 豪夫迈·罗氏有限公司 基于三维结构的人源化方法
MX2020002241A (es) 2017-08-28 2020-09-03 Angiex Inc Anticuerpos anti-tm4sf y métodos de uso de los mismos.
MX2020002612A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Anticuerpos de la proteina de muerte celular programada 1.
EP3456739A1 (de) 2017-09-19 2019-03-20 Tillotts Pharma Ag Verwendung von anti-tnfalpha antiköper in der behandlung von wunden
EP3459529A1 (de) 2017-09-20 2019-03-27 Tillotts Pharma Ag Herstellung von festen darreichungsformen mit verzögerter freisetzung mit antikörpern durch sprühtrocknung
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
EP3459528B1 (de) 2017-09-20 2022-11-23 Tillotts Pharma Ag Herstellung von festen darreichungsformen mit antikörpern durch lösungs-/suspensionsschichtung
MX2020003219A (es) 2017-09-21 2020-07-20 Imcheck Therapeutics Sas Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EP3692370A2 (de) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Artikel und verfahren zur personalisierten krebstherapie
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
US11332527B2 (en) 2017-10-12 2022-05-17 Keio University Anti AQP3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (AQP3) and use thereof
EA202090817A1 (ru) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. Триспецифические белки и способы их применения
WO2019075378A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B-MATURATION ANTIGEN BINDING PROTEINS
AU2018361957B2 (en) 2017-10-31 2023-05-25 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
US20190160089A1 (en) 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
CA3082365A1 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
CA3082410A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. Multifunctional immune cell therapies
EP3717069A1 (de) 2017-11-27 2020-10-07 Purdue Pharma L.P. Gegen menschlichen gewebefaktor gerichtete humanisierte antikörper
EP3732199A1 (de) 2017-12-27 2020-11-04 TeneoBio, Inc. Für cd3-delta-/epsilon-heterodimer spezifische antikörper
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
US20210085715A1 (en) 2018-02-23 2021-03-25 Cartherics Pty. Ltd. T cell disease treatment targeting tag-72
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
PE20201343A1 (es) 2018-04-02 2020-11-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
EP3784351A1 (de) 2018-04-27 2021-03-03 Novartis AG Car-t-zelltherapien mit erhöhter wirksamkeit
EP3784274A1 (de) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Gegen ein tau-abgeleitetes neurotoxisches peptid gerichteter antikörper und verwendungen davon
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
MX2020012598A (es) 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
US20210253688A1 (en) 2018-06-18 2021-08-19 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
TW202016142A (zh) 2018-06-18 2020-05-01 法商天賜製藥公司 用於治療癌症之組合物及方法
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
AU2019288677A1 (en) 2018-06-21 2021-01-14 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
WO2020002579A1 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
BR112021000300A2 (pt) 2018-07-10 2021-04-06 Mitsubishi Tanabe Pharma Corporation Método de prevenção ou tratamento para neuropatia periférica ou doença acompanhada de dor em que neuropatia periférica ou transtorno de astrocito é reconhecido
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
AU2019327569A1 (en) 2018-08-30 2021-04-29 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
WO2020061210A1 (en) 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
EP3856771A4 (de) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3-bindende proteine und verfahren zur verwendung
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
EP3856773A1 (de) 2018-09-28 2021-08-04 Kyowa Kirin Co., Ltd. Il-36-antikörper und verwendungen davon
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020094609A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
US20220026445A1 (en) 2018-12-07 2022-01-27 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
CA3123004A1 (en) 2018-12-11 2020-06-18 Q32 Bio Inc. Fusion protein constructs for complement associated disease
WO2020120786A1 (en) 2018-12-14 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
CA3124356A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
AU2019427766A1 (en) 2019-01-30 2021-09-16 Nomocan Pharmaceuticals Llc Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
SG11202107995SA (en) 2019-01-31 2021-08-30 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
AU2020218446B2 (en) 2019-02-04 2023-05-25 National University Corporation Ehime University "CAR LIBRARY AND scFv MANUFACTURING METHOD
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
CN112703013B (zh) 2019-02-22 2022-09-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用
CN112142847B (zh) 2019-02-22 2023-05-05 武汉友芝友生物制药股份有限公司 改造的Fc片段，包含其的抗体及其应用
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
US11242407B2 (en) 2019-02-26 2022-02-08 Inspirna, Inc. High-affinity anti-MERTK antibodies and uses thereof
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
SG11202109932WA (en) 2019-03-20 2021-10-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
CA3134495A1 (en) 2019-03-26 2020-10-01 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-il13r antibody or binding fragment thereof
CN113874392A (zh) 2019-03-28 2021-12-31 丹尼斯科美国公司 工程化抗体
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
EP3972998A1 (de) 2019-05-21 2022-03-30 Novartis AG Cd19-bindende moleküle und verwendungen davon
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
AU2020291938A1 (en) 2019-06-14 2022-01-20 Teneobio, Inc. Multispecific heavy chain antibodies binding to CD22 and CD3
AU2020298572A1 (en) 2019-07-02 2021-11-18 Fred Hutchinson Cancer Center Recombinant Ad35 vectors and related gene therapy improvements
EP3998286A4 (de) 2019-07-11 2023-04-26 Wuhan Yzy Biopharma Co., Ltd. Vierwertiger symmetrischer bispezifischer antikörper
EP4004050A2 (de) 2019-07-30 2022-06-01 QLSF Biotherapeutics Inc. Multispezifische bindungsverbindung mit bindung an lfrrc15 und cd3
EP4007775A1 (de) 2019-08-02 2022-06-08 Orega Biotech Neue il-17b-antikörper
JP2022545368A (ja) 2019-08-12 2022-10-27 アプティーボ リサーチ アンド デベロップメント エルエルシー ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
US20220348650A1 (en) 2019-09-03 2022-11-03 Bio-Thera Solutions, Ltd. Anti-tigit immunosuppressant and application thereof
WO2021062323A1 (en) 2019-09-26 2021-04-01 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
EP4034560A1 (de) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müller-hemmungssubstanz-antikörper und verwendungen davon
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
CN114829404A (zh) 2019-10-09 2022-07-29 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
EP3812008A1 (de) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-kompetitiver antagonistischer antikörper
EP3825330A1 (de) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117-antikörper und verfahren zur verwendung davon
EP4061944A1 (de) 2019-11-22 2022-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitoren von adrenomedullin zur behandlung von akuter myeloischer leukämie durch vernichtung von leukämischen stammzellen
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
EP4073117A1 (de) 2019-12-10 2022-10-19 Institut Pasteur Neuer antikörper, der menschliche fcgriiia und fcgriiib blockiert
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
JPWO2021145435A1 (de) 2020-01-15 2021-07-22
WO2021145432A1 (ja) 2020-01-15 2021-07-22 国立大学法人大阪大学 糖尿病性自律神経障害の予防又は治療剤
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Peptide-binding proteins and their uses
US20230192900A1 (en) 2020-02-13 2023-06-22 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
US20230125234A1 (en) 2020-02-13 2023-04-27 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
US20230151109A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
US20230096030A1 (en) 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
US11180563B2 (en) 2020-02-21 2021-11-23 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
US11879004B2 (en) 2020-02-28 2024-01-23 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
CA3174103A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4130035A1 (de) 2020-03-31 2023-02-08 Bio-Thera Solutions, Ltd. Antikörper und fusionsprotein zur behandlung von coronaviren und verwendung davon
EP4132971A1 (de) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinitätsgereifte anti-lap-antikörper und verwendungen davon
BR112022020592A2 (pt) 2020-04-24 2022-11-29 Sanofi Sa Combinações antitumor contendo conjugados de anticorpo anti-ceacam5, trifluridina e tipiracila
IL297222A (en) 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing conjugates of antibodies to ceacam5 and cetuximab
IL297311A (en) 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing conjugates of antibodies to ceacam5 and folfox
WO2021214221A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
CN113637082A (zh) 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
KR20230008751A (ko) 2020-05-12 2023-01-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
EP3915641A1 (de) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5-antikörper und verfahren zu ihrer verwendung
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
JPWO2022014703A1 (de) 2020-07-17 2022-01-20
CN114057877A (zh) 2020-08-07 2022-02-18 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
CN116113439A (zh) 2020-09-04 2023-05-12 默克专利股份公司 抗ceacam5抗体和缀合物及其用途
WO2022076712A2 (en) 2020-10-07 2022-04-14 Zoetis Services Llc Anti-ngf antibodies and methods of use thereof
EP3981789A1 (de) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb-antikörper und verwendungen davon
WO2022079199A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022082005A1 (en) 2020-10-16 2022-04-21 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
US20230406924A1 (en) 2020-11-02 2023-12-21 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
JP2023547506A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー Ｂ細胞悪性腫瘍を治療するための抗ｃｄ１９剤及びｂ細胞標的化剤の組み合わせ療法
WO2022095970A1 (zh) 2020-11-06 2022-05-12 百奥泰生物制药股份有限公司 双特异抗体及其应用
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
US20240033358A1 (en) 2020-11-13 2024-02-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
AU2021390501A1 (en) 2020-12-01 2023-06-29 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
AU2021398385A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Antibodies against interleukin-22
CN116670166A (zh) 2020-12-07 2023-08-29 Ucb生物制药有限责任公司 多特异性抗体和抗体组合
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240092892A1 (en) 2020-12-30 2024-03-21 Bio-Thera Solutions, Ltd. Anti-cldn18.2 antibody, and preparation method therefor and use thereof
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
AU2022208361A1 (en) 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Anti-dll3 antibody-drug conjugate
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022159575A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
JP2024505600A (ja) 2021-02-03 2024-02-06 モーツァルト セラピューティクス， インコーポレイテッド 結合剤およびそれを使用する方法
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022184910A1 (en) 2021-03-04 2022-09-09 Centre National De La Recherche Scientifique (Cnrs) Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
BR112023017490A2 (pt) 2021-03-17 2023-11-07 Receptos Llc Métodos de tratamento de dermatite atópica com anticorpos anti il-13
BR112023019205A2 (pt) 2021-03-26 2023-10-24 Janssen Biotech Inc Anticorpos humanizados contra tau de filamento helicoidal pareado e usos dos mesmos
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CN117642428A (zh) 2021-05-03 2024-03-01 Ucb生物制药有限责任公司 抗体
EP4334353A1 (de) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispezifische fgf21-rezeptoragonisten und deren verwendungen
EP4334354A1 (de) 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Antikörper gegen alk und verfahren zur verwendung davon
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
AR126161A1 (es) 2021-06-17 2023-09-27 Boehringer Lngelheim Int Gmbh Moléculas de fijación triespecíficas novedosas
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
TW202321287A (zh) 2021-07-29 2023-06-01 日商武田藥品工業股份有限公司 特異性靶向間皮素之經工程改造之免疫細胞及其用途
CA3226537A1 (en) 2021-07-29 2023-02-02 Ana HENNINO Humanized anti-human .beta.ig-h3 protein and uses thereof
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3227511A1 (en) 2021-08-06 2023-02-09 Lætitia LINARES Methods for the treatment of cancer
AU2022325950A1 (en) 2021-08-11 2024-02-22 Viela Bio, Inc. Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
TW202325733A (zh) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 抗醣化-lamp1抗體及其用途
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗ｉｌ１３ｒ抗體調配物
TW202333797A (zh) 2021-11-05 2023-09-01 法商賽諾菲公司 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
US20230227545A1 (en) 2022-01-07 2023-07-20 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
WO2023170239A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Methods and tools for conjugation to antibodies
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
WO2023170291A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
WO2023170290A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
WO2023170295A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
EP4245772A1 (de) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1-antikörper zur behandlung von leberentzündung
EP4249509A1 (de) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1-antikörper gegen arthritis-assoziierte schmerzen
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
GB202210680D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-35r
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
EP0365209A3 (de) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Aminosäuresequenz des Anti-leu 3a
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5062934A (en) * 1989-12-18 1991-11-05 Oronzio Denora S.A. Method and apparatus for cathodic protection
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DK0531472T3 (da) * 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
AU668864B2 (en) * 1991-03-18 1996-05-23 Centocor Inc. Chimeric antibodies specific for human tumor necrosis factor
JPH06202412A (ja) * 1992-12-26 1994-07-22 Canon Inc 画像形成装置
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5535089A (en) * 1994-10-17 1996-07-09 Jing Mei Industrial Holdings, Ltd. Ionizer

Also Published As

Publication number Publication date
EP0626390A1 (de) 1994-11-30
EP0626390B1 (de) 2001-11-14
DK0626390T3 (da) 2002-03-11
US20050202529A1 (en) 2005-09-15
EP0460167B1 (de) 1995-10-11
CA2050479A1 (en) 1991-06-22
EP0460171B1 (de) 1995-06-28
RU2112037C1 (ru) 1998-05-27
KR920701465A (ko) 1992-08-11
ATE159299T1 (de) 1997-11-15
HUT60786A (en) 1992-10-28
GR3017734T3 (en) 1996-01-31
HUT58372A (en) 1992-02-28
HU215383B (hu) 2000-03-28
AU646009B2 (en) 1994-02-03
HUT58824A (en) 1992-03-30
FI913926A0 (fi) 1991-08-20
AU664801B2 (en) 1995-11-30
CA2046904A1 (en) 1991-06-22
ATE129017T1 (de) 1995-10-15
FI109768B (fi) 2002-10-15
ZA9110129B (en) 1993-06-23
FI913932A0 (fi) 1991-08-20
DK0460171T3 (da) 1995-08-28
AU6461294A (en) 1994-12-22
US20060073137A1 (en) 2006-04-06
JPH05500312A (ja) 1993-01-28
ATE208794T1 (de) 2001-11-15
CA2037607C (en) 2005-05-24
DE69033857D1 (de) 2001-12-20
RO114298B1 (ro) 1999-03-30
WO1991009968A1 (en) 1991-07-11
EP0460167A1 (de) 1991-12-11
US20060073136A1 (en) 2006-04-06
NO913228L (no) 1991-10-21
GB2268744B (en) 1994-05-11
DK0460178T3 (da) 1997-12-22
JPH11243955A (ja) 1999-09-14
NO985467D0 (no) 1998-11-23
NO913229D0 (no) 1991-08-19
US20040071693A1 (en) 2004-04-15
JP3242913B2 (ja) 2001-12-25
US20040076627A1 (en) 2004-04-22
DE69022982T2 (de) 1996-03-28
US7262050B2 (en) 2007-08-28
ES2079638T3 (es) 1996-01-16
ATE124459T1 (de) 1995-07-15
NO985468L (no) 1991-10-21
WO1991009967A1 (en) 1991-07-11
KR100197956B1 (ko) 1999-06-15
FI913927A0 (fi) 1991-08-20
US5929212A (en) 1999-07-27
US7241877B2 (en) 2007-07-10
NO913228D0 (no) 1991-08-19
GB2246781A (en) 1992-02-12
HU912751D0 (en) 1992-01-28
GB9117612D0 (en) 1991-11-20
GB2246781B (en) 1994-05-11
GB2246570B (en) 1994-05-11
CA2037607A1 (en) 1992-09-07
DK0460167T3 (da) 1995-11-20
HU217693B (hu) 2000-03-28
HU912752D0 (en) 1992-01-28
NO316074B1 (no) 2003-12-08
DE69031591T2 (de) 1998-03-12
RO114232B1 (ro) 1999-02-26
FI990875A0 (fi) 1999-04-19
NO985468D0 (no) 1998-11-23
NO310560B1 (no) 2001-07-23
FI990875A (fi) 1999-04-19
AU7033091A (en) 1991-07-24
FI108917B (fi) 2002-04-30
ES2165864T3 (es) 2002-04-01
BG60462B1 (bg) 1995-04-28
DE69020544D1 (de) 1995-08-03
NO316076B1 (no) 2003-12-08
CA2050479C (en) 1997-03-25
KR100191152B1 (ko) 1999-06-15
GB8928874D0 (en) 1990-02-28
AU7048691A (en) 1991-07-24
GB2268744A (en) 1994-01-19
EP0460178B1 (de) 1997-10-15
US7244832B2 (en) 2007-07-17
DE69033857T2 (de) 2002-09-12
FI108777B (fi) 2002-03-28
GB9318911D0 (en) 1993-10-27
GR3025781T3 (en) 1998-03-31
FI108776B (fi) 2002-03-28
US20040202662A1 (en) 2004-10-14
AU6974091A (en) 1991-07-24
AU649645B2 (en) 1994-06-02
ES2074701T3 (es) 1995-09-16
JPH04506458A (ja) 1992-11-12
US20060029593A1 (en) 2006-02-09
CA2046904C (en) 2003-12-02
US20050123534A1 (en) 2005-06-09
NO913271L (no) 1991-08-20
EP0460171A1 (de) 1991-12-11
RO114980B1 (ro) 1999-09-30
BR9007197A (pt) 1992-01-28
US20050136054A1 (en) 2005-06-23
EP0620276A1 (de) 1994-10-19
DE69020544T2 (de) 1996-01-18
JP3452062B2 (ja) 2003-09-29
KR100198478B1 (en) 1999-06-15
ES2112270T3 (es) 1998-04-01
GB9117611D0 (en) 1991-10-02
JPH04505398A (ja) 1992-09-24
DE69031591D1 (de) 1997-11-20
WO1991009966A1 (en) 1991-07-11
AU631481B2 (en) 1992-11-26
NO913271D0 (no) 1991-08-20
NO985467L (no) 1991-10-21
US7244615B2 (en) 2007-07-17
GB2246570A (en) 1992-02-05
NO913229L (no) 1991-10-21
EP0460178A1 (de) 1991-12-11

Similar Documents

Publication Publication Date Title
DE69022982D1 (de) Humanisierte antikörper.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation